The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
NAFLD and cardiovascular diseases: a clinical review
Open accessAbstract
Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in Western countries and affects approximately 25% of the adult population. Since NAFLD is frequently associated with further metabolic comorbidities such as obesity, type 2 diabetes mellitus, or dyslipidemia, it is generally considered as the hepatic manifestation of the metabolic syndrome. In addition to its potential to cause liver-related morbidity and mortality, NAFLD is also associated with subclinical and clinical cardiovascular disease (CVD). Growing evidence indicates that patients with NAFLD are at substantial risk for the development of hypertension, coronary heart disease, cardiomyopathy, and cardiac arrhythmias, which clinically result in increased cardiovascular morbidity and mortality. The natural history of NAFLD is variable and the vast majority of patients will not progress from simple steatosis to fibrosis and end stage liver disease. However, patients with progressive forms of NAFLD, including non-alcoholic steatohepatitis (NASH) and/or advanced fibrosis, as well as NAFLD patients with concomitant types 2 diabetes are at highest risk for CVD. This review describes the underlying pathophysiological mechanisms linking NAFLD and CVD, discusses the role of NAFLD as a metabolic dysfunction associated cardiovascular risk factor, and focuses on common cardiovascular manifestations in NAFLD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C., & Cao, C. Y. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 93
RetractedWithdrawal: Hepatic manifestations of metabolic syndrome
Medina‐Santillán, R., López‐Velázquez, J. A., Chávez-Tapia, N. C., Torres‐Villalobos, G., Uribe, M., & Méndez‐Sánchez, N. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2410 · Cited by 46
RetractedJames, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755 · cited 1×
“This is in line with general physical exercise recommendations for improved cardiometabolic health and reduced cardiovascular morbidity in adults, namely 150–300 min of moderate-intensity or 75–150 min of vigorous-intensity activity weekly, supplemented by two sessions of muscle-building exercise and less sedentary ti…”
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858 · cited 1×
“Across European countries NAFLD affects approximately 1 in 4 members of the general population with a gradient of higher prevalence from Southern to Northern Europe [15].”
BackgroundEffects of intermittent fasting on health, aging, and disease
de Cabo, R., & Mattson, M. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1905136 · Cited by 1,605 · cited 4×
“Intermittent fasting with energy restriction for about 10-16 h is promising approach in this context, as it has been shown to mediate robust disease modifying effects on chronic metabolic disorders such as obesity, T2DM and CVD [156].”
BackgroundInfluentialBorén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Body Fat Distribution and Risk of Cardiovascular Disease: An Update
Després, J.-P. (2012) · Circulation · doi:10.1161/circulationaha.111.067264 · Cited by 1,481
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,174
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,060
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Huang, C.-F., Chang, Y.-J., Hsueh, Y.-Y., Huang, C.-W., Wang, D.-H., Huang, T.-C., Wu, Y.-T., Su, F.-C., Hughes, M., Chuong, C.-M., et al. (2016) · Scientific Reports · doi:10.1038/srep31257 · Cited by 941
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Insulin resistance and hyperglycaemia in cardiovascular disease development
Laakso, M., & Kuusisto, J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.29 · Cited by 858
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806
Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors
Fiuza-Luces, C., Santos-Lozano, A., Joyner, M., Carrera-Bastos, P., Picazo, O., Zugaza, J. L., Izquierdo, M., Ruilope, L. M., & Lucia, A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0065-1 · Cited by 803
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
Söderberg, C., Stål, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., & Hultcrantz, R. (2010) · Hepatology · doi:10.1002/hep.23314 · Cited by 754
Hypertension and cardiovascular risk: General aspects
Kjeldsen, S. E. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.003 · Cited by 694 · cited 1×
“1 3 and progression of heart failure, peripheral arterial occlusive disease and cardiac arrhythmias, especially atrial fibrillation [94, 95].”
BackgroundPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656 · cited 7×
“leptin, tumor necrosis factor-a, IL 1-b and IL-6, and resistin) that promote the infiltration of macrophages, destroy microvascular systems, and activate profibrotic pathways [59, 65, 66].”
BackgroundInfluentialEndothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease†
Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., Zoli, M., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20781 · Cited by 629
The Natural Course of Non-Alcoholic Fatty Liver Disease
Calzadilla Bertot, L., & Adams, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 620
Francque, S. M., van der Graaff, D., & Kwanten, W. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.005 · Cited by 556
Exome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Keating, S. E., Hackett, D. A., George, J., & Johnson, N. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.023 · Cited by 537
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533
Thoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506
Intestinal Microbiota in Cardiovascular Health and Disease
Tang, W. H. W., Bäckhed, F., Landmesser, U., & Hazen, S. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.024 · Cited by 502
Promoting Physical Activity and Exercise
Fletcher, G. F., Landolfo, C., Niebauer, J., Ozemek, C., Arena, R., & Lavie, C. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2141 · Cited by 489
Mardinoglu, A., Wu, H., Bjornson, E., Zhang, C., Hakkarainen, A., Räsänen, S. M., Lee, S., Mancina, R. M., Bergentall, M., Pietiläinen, K. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.01.005 · Cited by 453
Nonalcoholic Fatty Liver Disease and the Heart
Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N. P., & Sperling, L. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.050 · Cited by 439
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · cited 1×
“1 3 of lipid oxidation, inflammation, and endothelial function [148, 149].”
BackgroundVaccarino, V., Badimon, L., Bremner, J. D., Cenko, E., Cubedo, J., Dorobantu, M., Duncker, D. J., Koller, A., Manfrini, O., Milicic, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehy913 · Cited by 404
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study
Lazo, M., Hernaez, R., Bonekamp, S., Kamel, I. R., Brancati, F. L., Guallar, E., & Clark, J. M. (2011) · BMJ · doi:10.1136/bmj.d6891 · Cited by 395
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., et al. (2020) · Hepatology · doi:10.1002/hep.31108 · Cited by 378
Lechner, K., von Schacky, C., McKenzie, A. L., Worm, N., Nixdorff, U., Lechner, B., Kränkel, N., Halle, M., Krauss, R. M., & Scherr, J. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319869400 · Cited by 371
Allen, A. M., Therneau, T. M., Larson, J. J., Coward, A., Somers, V. K., & Kamath, P. S. (2018) · Hepatology · doi:10.1002/hep.29546 · Cited by 370
Environmental stressors and cardio-metabolic disease: part II–mechanistic insights
Münzel, T., Sørensen, M., Gori, T., Schmidt, F. P., Rao, X., Brook, F. R., Chen, L. C., Brook, R. D., & Rajagopalan, S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw294 · Cited by 367
Oni, E. T., Agatston, A. S., Blaha, M. J., Fialkow, J., Cury, R., Sposito, A., Erbel, R., Blankstein, R., Feldman, T., Al-Mallah, M. H., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.052 · Cited by 352
Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology · doi:10.1002/hep.26393 · Cited by 350
Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., & Zhang, Z. (2016) · Scientific Reports · doi:10.1038/srep33386 · Cited by 318
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310 · cited 2×
“The increased risk of cardiac arrhythmias, especially ventricular tachyarrhythmias, could further contribute to the increased risk of CVD morbidity and mortality among NAFLD patients [124].”
BackgroundVanWagner, L. B., Wilcox, J. E., Colangelo, L. A., Lloyd‐Jones, D. M., Carr, J. J., Lima, J. A., Lewis, C. E., Rinella, M. E., & Shah, S. J. (2015) · Hepatology · doi:10.1002/hep.27869 · Cited by 305
Münzel, T., Sørensen, M., Gori, T., Schmidt, F. P., Rao, X., Brook, J., Chen, L. C., Brook, R. D., & Rajagopalan, S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw269 · Cited by 293
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
Anand, S. S., Yi, Q., Gerstein, H., Lonn, E., Jacobs, R., Vuksan, V., Teo, K., Davis, B., Montague, P., & Yusuf, S. (2003) · Circulation · doi:10.1161/01.cir.0000080884.27358.49 · Cited by 285
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation
Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S. J., Schmit, D., Kramann, R., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0548-1 · Cited by 280
Gepner, Y., Shelef, I., Schwarzfuchs, D., Zelicha, H., Tene, L., Yaskolka Meir, A., Tsaban, G., Cohen, N., Bril, N., Rein, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030501 · Cited by 279 · cited 5×
“This accumulation of (visceral and) ectopic fat and the subsequent release of fat-derived toxic metabolites together with an activation of inflammatory pathways instigates a cluster of local and systemic pathophysiological changes that ultimately leads to the development of both NAFLD and cardiovascular diseases, poss…”
BackgroundInfluentialKoutoukidis, D. A., Astbury, N. M., Tudor, K. E., Morris, E., Henry, J. A., Noreik, M., Jebb, S. A., & Aveyard, P. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2248 · Cited by 270
Toll-like Receptors in the Vascular System: Sensing the Dangers Within
Goulopoulou, S., McCarthy, C. G., & Webb, R. C. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.010090 · Cited by 263
Psychosocial stress and cardiovascular disease
Dar, T., Radfar, A., Abohashem, S., Pitman, R. K., Tawakol, A., & Osborne, M. T. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0724-5 · Cited by 248
Yerramasu, A., Dey, D., Venuraju, S., Anand, D. V., Atwal, S., Corder, R., Berman, D. S., & Lahiri, A. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.09.041 · Cited by 240
Hwang, D. H., Kim, J.-A., & Lee, J. Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.024 · Cited by 238
Gepner, Y., Shelef, I., Komy, O., Cohen, N., Schwarzfuchs, D., Bril, N., Rein, M., Serfaty, D., Kenigsbuch, S., Zelicha, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.013 · Cited by 236
Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat
Schwarz, J.-M., Noworolski, S. M., Wen, M. J., Dyachenko, A., Prior, J. L., Weinberg, M. E., Herraiz, L. A., Tai, V. W., Bergeron, N., Bersot, T. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3678 · Cited by 229
Over-expression of COX-2 mRNA in colorectal cancer
Roelofs, H. M., te Morsche, R. H., van Heumen, B. W., Nagengast, F. M., & Peters, W. H. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-1 · Cited by 224
The Role of Gut Microbiota in Atherosclerosis and Hypertension
Ma, J., & Li, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01082 · Cited by 224
Lauridsen, B. K., Stender, S., Kristensen, T. S., Kofoed, K. F., Køber, L., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx662 · Cited by 213
Association of sleep disturbances with obesity, insulin resistance and the metabolic syndrome
Koren, D., & Taveras, E. M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.04.001 · Cited by 207
Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., Zoppini, G., Mantovani, W., Barbieri, E., & Byrne, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057183 · Cited by 197
Jordan, J., Kurschat, C. E., & Reuter, H. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0557 · Cited by 196
Role of Epicardial Adipose Tissue in Health and Disease: A Matter of Fat?
Gaborit, B., Sengenès, C., Ancel, P., Jacquier, A., & Dutour, A. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160034 · Cited by 195
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Ismaiel, A., & Dumitraşcu, D. L. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00202 · Cited by 192
Procoagulant imbalance in patients with non-alcoholic fatty liver disease
Tripodi, A., Fracanzani, A. L., Primignani, M., Chantarangkul, V., Clerici, M., Mannucci, P. M., Peyvandi, F., Bertelli, C., Valenti, L., & Fargion, S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.013 · Cited by 192
Mahfood Haddad, T., Hamdeh, S., Kanmanthareddy, A., & Alla, V. M. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.033 · Cited by 182
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.061 · Cited by 180
Glass, L. M., Dickson, R. C., Anderson, J. C., Suriawinata, A. A., Putra, J., Berk, B. S., & Toor, A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3380-3 · Cited by 176
Loomba, R. S., & Adams, L. A. (2019) · Hepatology · doi:10.1002/hep.30946 · Cited by 175
Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction
White, M. G., Shaw, J. A. M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc16-0619 · Cited by 174
Enhanced Inflammation in Epicardial Fat in Patients With Coronary Artery Disease
Hirata, Y., Kurobe, H., Akaike, M., Chikugo, F., Hori, T., Bando, Y., Nishio, C., Higashida, M., Nakaya, Y., Kitagawa, T., et al. (2011) · International Heart Journal · doi:10.1536/ihj.52.139 · Cited by 173
Long QT Syndrome: An Emerging Role for Inflammation and Immunity
Lazzerini, P. E., Capecchi, P. L., & Laghi-Pasini, F. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00026 · Cited by 172
Nasr, P., Ignatova, S., Kechagias, S., & Ekstedt, M. (2017) · Hepatology Communications · doi:10.1002/hep4.1134 · Cited by 171
Brunt, E. M., Neuschwander-Tetri, B. A., Oliver, D., Wehmeier, K. R., & Bacon, B. R. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.04.017 · Cited by 167
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis
Lee, J. J., Lambert, J. E., Hovhannisyan, Y., Ramos-Roman, M. A., Trombold, J. R., Wagner, D. A., & Parks, E. J. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.092262 · Cited by 164
Chang, Y., Ryu, S., Sung, K.-C., Cho, Y. K., Sung, E., Kim, H.-N., Jung, H.-S., Yun, K. E., Ahn, J., Shin, H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317666 · Cited by 164
Local adipose tissue depots as cardiovascular risk factors
THALMANN, S., & MEIER, C. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.008 · Cited by 163
Sinn, D. H., Kang, D., Chang, Y., Ryu, S., Gu, S., Kim, H., Seong, D., Cho, S. J., Yi, B.-K., Park, H.-D., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311854 · Cited by 163
Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease
Hallsworth, K., Hollingsworth, K. G., Thoma, C., Jakovljević, D. G., MacGowan, G. A., Anstee, Q. M., Taylor, R., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.015 · Cited by 162
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease
Pastori, D., Polimeni, L., Baratta, F., Pani, A., Del Ben, M., & Angelico, F. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.07.170 · Cited by 162
Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss
Al-Mrabeh, A., Zhyzhneuskaya, S. V., Peters, C., Barnes, A. C., Melhem, S., Jesuthasan, A., Aribisala, B., Hollingsworth, K. G., Lietz, G., Mathers, J. C., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.018 · Cited by 162
Procoagulant imbalance in patients with non-alcoholic fatty liver disease
Tripodi, A., Fracanzani, A. L., Chantarangkul, V., Primignani, M., & Fargion, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.025 · Cited by 161
Cardiac Autonomic Dysfunction and Incidence of Atrial Fibrillation
Agarwal, S. K., Norby, F. L., Whitsel, E. A., Soliman, E. Z., Chen, L. Y., Loehr, L. R., Fuster, V., Heiss, G., Coresh, J., & Alonso, A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.059 · Cited by 161
S2k-Leitlinie nicht alkoholische Fettlebererkrankungen
Roeb, E., Steffen, H., Bantel, H., Baumann, U., Canbay, A., Demir, M., Drebber, U., Geier, A., Hampe, J., Hellerbrand, C., et al. (2015) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0035-1553193 · Cited by 161
Self-citationEmdin, C. A., Haas, M. E., Khera, A. V., Aragam, K., Chaffin, M., Klarin, D., Hindy, G., Jiang, L., Wei, W.-Q., Feng, Q., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008629 · Cited by 161
Lechner, K., McKenzie, A. L., Kränkel, N., von Schacky, C., Worm, N., Nixdorff, U., Lechner, B., Scherr, J., Weingärtner, O., & Krauss, R. M. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0115 · Cited by 159
Käräjämäki, A. J., Pätsi, O.-P., Savolainen, M. J., Kesäniemi, Y. A., Huikuri, H. V., & Ukkola, O. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142937 · Cited by 157
Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver
Sung, K., Ryu, S., Lee, J., Kim, J., Wild, S. H., & Byrne, C. D. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.026 · Cited by 156
Aneni, E. C., Oni, E., Martin, S. S., Blaha, M. J., Agatston, A. S., Feldman, T., Veledar, E., Conceição, R., Carvalho, J. A. M., Santos, R. D., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000532 · Cited by 155
Are Lifestyle Therapies Effective for NAFLD Treatment?
El-Agroudy, N. N., Kurzbach, A., Rodionov, R. N., O’Sullivan, J., Roden, M., Birkenfeld, A. L., & Pesta, D. H. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.07.013 · Cited by 152
Abdominal Superficial Subcutaneous Fat
Golan, R., Shelef, I., Rudich, A., Gepner, Y., Shemesh, E., Chassidim, Y., Harman‐Boehm, I., Henkin, Y., Schwarzfuchs, D., Avraham, S. B., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1583 · Cited by 150
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease
Coulon, S., Francque, S., Colle, I. O., Verrijken, A., Blomme, B., Heindryckx, F., Munter, S. D., Prawitt, J., Caron, S., Staels, B., et al. (2012) · Cytokine · doi:10.1016/j.cyto.2012.05.001 · Cited by 148
Oh, S., So, R., Shida, T., Matsuo, T., Kim, B., Akiyama, K., Isobe, T., Okamoto, Y., Tanaka, K., & Shoda, J. (2017) · Scientific Reports · doi:10.1038/srep43029 · Cited by 146
Novel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
Clinical association between non‐alcoholic fatty liver disease and the development of hypertension
Ryoo, J., Suh, Y. J., Shin, H. C., Cho, Y. K., Choi, J., & Park, S. K. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12643 · Cited by 139
The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD
Francisco Barrera, M., & George, J. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.009 · Cited by 139
Pastore, A., Alisi, A., Giovamberardino, G. D., Crudele, A., Ceccarelli, S., Panera, N., Dionisi‐Vici, C., & Nobili, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151121202 · Cited by 134
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Lu, W., Li, S., Li, J., Wang, J., Zhang, R., Zhou, Y., Yin, Q., Zheng, Y., Wang, F., Xia, Y., et al. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/1459790 · Cited by 131
Fructose-containing caloric sweeteners as a cause of obesity and metabolic disorders
Tappy, L. (2018) · Journal of Experimental Biology · doi:10.1242/jeb.164202 · Cited by 130
Mantovani, A., Rigamonti, A., Bonapace, S., Bolzan, B., Pernigo, M., Morani, G., Franceschini, L., Bergamini, C., Bertolini, L., Valbusa, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0091 · Cited by 129
Hafliðadóttir, S., Jonasson, J. G., Norland, H., Einarsdottir, S., Kleiner, D. E., Lund, S. H., & Bjornsson, E. S. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-166 · Cited by 126
Zhou, Y.-Y., Zhou, X.-D., Wu, S.-J., Hu, X.-Q., Tang, B., Poucke, S. V., Pan, X.-Y., Wu, W.-J., Gu, X.-M., Fu, S.-W., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001075 · Cited by 125
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
de Carvalho, S. C. R., Muniz, M. T. C., Siqueira, M. D. V., de Siqueira, É. R. F., Gomes, A. V., da Silva, K. A., Bezerra, L. C. L., D’Almeida, V., de Oliveira, C. P. M. S., & Pereira, L. M. M. B. (2013) · Nutrition Journal · doi:10.1186/1475-2891-12-37 · Cited by 116
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Volk, B. M., Kunces, L. J., Freidenreich, D. J., Kupchak, B. R., Saenz, C., Artistizabal, J. C., Fernandez, M. L., Bruno, R. S., Maresh, C. M., Kraemer, W. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113605 · Cited by 112
Ergatoudes, C., Schaufelberger, M., Andersson, B., Pivodic, A., Dahlström, U., & Fu, M. L. X. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01430-0 · Cited by 103
Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease
Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Valbusa, F., Bertolini, L., Zenari, L., Pichiri, I., Dauriz, M., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.04.003 · Cited by 101
Nonalcoholic Fatty Liver Disease and Incident Cardiac Events
Zeb, I., Li, D., Budoff, M. J., Katz, R., Lloyd‐Jones, D. M., Agatston, A. A., Blumenthal, R. S., Blaha, M. J., Blankstein, R., Carr, J. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.070 · Cited by 101
Raj, H., Durgia, H., Palui, R., Kamalanathan, S., Selvarajan, S., Kar, S. S., & Sahoo, J. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i2.114 · Cited by 101
Jaruvongvanich, V., Wirunsawanya, K., Sanguankeo, A., & Upala, S. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.09.002 · Cited by 98
Marinho, T. D. S., Ornellas, F., Barbosa‐da‐Silva, S., Mandarim‐de‐Lacerda, C. A., & Águila, M. B. (2019) · Nutrition · doi:10.1016/j.nut.2019.02.020 · Cited by 89
Keskin, M., Hayıroğlu, M. İ., Uzun, A. O., Güvenç, T. S., Şahin, S., & Kozan, Ö. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.107 · Cited by 83
Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD
Worm, N. (2020) · Nutrients · doi:10.3390/nu12051316 · Cited by 83
Mantovani, A., Mingolla, L., Rigolon, R., Pichiri, I., Cavalieri, V., Zoppini, G., Lippi, G., Bonora, E., & Targher, G. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.040 · Cited by 82
Shibasaki, I., Nishikimi, T., Mochizuki, Y., Yamada, Y., Yoshitatsu, M., Inoue, Y., Kuwata, T., Ogawa, H., Tsuchiya, G., Ishimitsu, T., et al. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.07.169 · Cited by 78
Bonnet, F., Gastaldelli, A., Bars, F. P., Natali, A., Roussel, R., Petrie, J. R., Tichet, J., Marre, M., Fromenty, B., & Balkau, B. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001204 · Cited by 78
Mantovani, A. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00005 · Cited by 77
Lau, K., Lorbeer, R., Haring, R., Schmidt, C. O., Wallaschofski, H., Nauck, M. A., John, U., Baumeister, S. E., & Völzke, H. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833c211b · Cited by 76
Sinha, S. K., Thakur, R., Jha, M. J., Goel, A., Kumar, V., Kumar, A., Mishra, V., Varma, C. M., Krishna, V., Singh, A. K., et al. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2468w · Cited by 71
Packer, M. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.09.002 · Cited by 67
Mariani, S., Fiore, D., Bárbaro, G., Basciani, S., Saponara, M., D’Arcangelo, E., Ulisse, S., Moretti, C., Fabbri, A., & Gnessi, L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.011 · Cited by 65
The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Wong, C. R., & Lim, J. K. (2018) · Clinical Liver Disease · doi:10.1002/cld.721 · Cited by 64
Fracanzani, A. L., Pisano, G., Consonni, D., Tiraboschi, S., Baragetti, A., Bertelli, C., Norata, G. D., Dongiovanni, P., Valenti, L. V. C., Grigore, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162473 · Cited by 63
Bonapace, S., Valbusa, F., Bertolini, L., Pichiri, I., Mantovani, A., Rossi, A., Zenari, L., Barbieri, E., & Targher, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088371 · Cited by 62
Picard, F. A., Guéret, P., Laissy, J., Champagne, S., Leclercq, F., Carrié, D., Juliard, J., Henry, P., Niarra, R., Châtellier, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110005 · Cited by 61
Echocardiography and NAFLD (non-alcoholic fatty liver disease)
Trovato, F. M., Martines, G. F., Catalano, D., Musumeci, G., Pirri, C., & Trovato, G. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.180 · Cited by 61
Osawa, K., Miyoshi, T., Yamauchi, K., Koyama, Y., Nakamura, K., Sato, S., Kanazawa, S., & Ito, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131138 · Cited by 58
Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study
Long, M. T., Yin, X., Larson, M. G., Ellinor, P. T., Lubitz, S. A., McManus, D. D., Magnani, J. W., Stærk, L., Ko, D., Helm, R. H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005227 · Cited by 58
High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD
Lang, S., Martin, A., Farowski, F., Wisplinghoff, H., Vehreschild, M. J. G. T., Liu, J., Krawczyk, M. J., Nowag, A., Kretzschmar, A., Herweg, J., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1509 · Cited by 58
Self-citationLai, H. T. M., Otto, M. C. D. O., Lee, Y., Wu, J. H. Y., Song, X., King, I. B., Psaty, B. M., Lemaître, R. N., McKnight, B., Siscovick, D. S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012881 · Cited by 53
Phenotyping non‐alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
Demir, M., Lang, S., Martin, A., Farowski, F., Wisplinghoff, H., Vehreschild, M. J. G. T., Krawczyk, M. J., Nowag, A., Scholz, C. J., Kretzschmar, A., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15071 · Cited by 53
Self-citationGruzdeva, O. V., Учасова, Е. Г., Dyleva, Y. A., Borodkinа, D. A., Евгеньевна, А. О., Antonova, L. V., Матвеева, В. Г., Belik, E. V., Ivanov, S. V., Sotnikov, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02163 · Cited by 51
Li, Y., Xu, H. W., Wu, W., Ye, J., Fang, D., Shi, D., & Li, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23816 · Cited by 45
Epicardial fat volume correlates with severity of coronary artery disease in nonobese patients
Okada, K., Ohshima, S., Isobe, S., Harada, K., Hirashiki, A., Funahashi, H., Arai, K., Hayashi, D., Hayashi, M., Ishii, H., et al. (2013) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32836094da · Cited by 39
Tsaban, G., Wolak, A., Avni-Hassid, H., Gepner, Y., Shelef, I., Henkin, Y., Schwarzfuchs, D., Cohen, N., Bril, N., Rein, M., et al. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.157115 · Cited by 39
Vasunta, R.-L., Kesäniemi, Y. A., Ylitalo, A. S., & Ukkola, O. H. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283576faf · Cited by 38
Association of Serum Homocysteine Levels with Histological Severity of NAFLD
Xu, Y., Guan, Y., Yang, X., Xia, Z., & Wu, J. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-529 · Cited by 36
Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease
Janssen, A., Grobbee, D. E., & Dendale, P. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319891783 · Cited by 35
Kim, H. W., Lee, D. H., Lee, S. A., & Koh, G. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1001-5 · Cited by 29
Primary non alcoholic fatty liver disease in hypertensive patients
Lăţea, L., Negrea, S., & Bolboaca, S. (2013) · Australasian Medical Journal · doi:10.21767/amj.2013.1648 · Cited by 29
Scholz, G. H., & Hanefeld, M. (2016) · Visceral Medicine · doi:10.1159/000450866 · Cited by 29
Monfort, A., Inamo, J., Fagour, C., Banydeen, R., Enette, L., René‐Corail, P., Rivkine, E., & Nevière, R. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01454-6 · Cited by 16
Mach, L., Bedáňová, H., Souček, M., Karpíšek, M., Konečný, T., Němec, P., & Orban, M. (2016) · Perfusion · doi:10.1177/0267659116683791 · Cited by 15
Schweinlin, A., Ulbrich, S. E., Stauß, S., Teutsch, M., Walle, H., Basrai, M., & Bischoff, S. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0668-2891 · Cited by 15
Singh, A., Kumar, M. S., Jaryal, A. K., Ranjan, P., Deepak, K. K., Sharma, S., Ramakrishnan, L., Pandey, R. M., & Vikram, N. K. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000898 · Cited by 7
Cited by
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Lipogenesis inhibitors: therapeutic opportunities and challenges
Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00367-2 · Cited by 399
Toh, J. Z. K., Pan, X.-H., Tay, P. W. L., Ng, C. H., Yong, J. N., Xiao, J., Koh, J. H., Tan, E. Y., Tan, E. X. X., Dan, Y. Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.021 · Cited by 130
The Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
“because it is strongly associated with obesity, type 2 diabetes, dyslipidemia, and cardiovascular disease.(2) The collective term NAFLD encompasses various phenotypes of metabolic liver disease, ranging from simple fat accumulation termed hepatic steatosis or nonalcoholic fatty liver, to nonalcoholic steatohepatitis (…”
BackgroundBi, Y., Guo, X., Zhang, M., Zhu, K., Shi, C., Fan, B., Wu, Y., Yang, Z., & Ji, G. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02663-5 · Cited by 82
Metadata
- Authors
- Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M.
- Venue
- Clinical Research in Cardiology
- Published
- 2020-07-21
- Volume
- 110
- Issue
- 7
- Pages
- 921-937
- ISSN
- 1861-0684 (ISSN-L)
- 1861-0692
- OpenAlex
- W3044005771
- Cited by
- 632
- References
- 171
- FWCI
- 47.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.